Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria

References

• World Health Organisation. Global tuberculosis report 2014. WHO Press; Geneva, Switzerland: 2014
   Google Scholar
• Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-3
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21
   PubMed Web of Science ®Google Scholar
• Saltini C. Chemotherapy and diagnosis of tuberculosis. Respir Med 2006;100:2085-97
   PubMedGoogle Scholar
• Zhang Y, Shi W, Zhang W, et al. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr 2013;2:1-12
   PubMedGoogle Scholar
• Murray MF. Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Clin Infect Dis 2003;36:453-60
   PubMed Web of Science ®Google Scholar
• Almeida D, Nuermberger E, Tasneen R, et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009;53:4178-84
   PubMed Web of Science ®Google Scholar
• Tarshis MS, Weed WA. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 1953;67:391-5
   PubMedGoogle Scholar
• Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988;32:1002-4
   PubMed Web of Science ®Google Scholar
• Werngren J, Sturegård E, Juréen P, et al. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012;56:1253-7
   PubMedGoogle Scholar
• Wade MM, Zhang Y. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 2004;53:769-73
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen ZF, Li YY, et al. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy 2007;53:338-43
   PubMedGoogle Scholar
• Wade MM, Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2006;58:936-41
   PubMed Web of Science ®Google Scholar
• Gu P, Constantino L, Zhang Y. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol 2008;57:1129-34
   PubMedGoogle Scholar
• Somoskovi A, Wade MM, Sun Z, et al. Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother 2004;53:192-6
   PubMed Web of Science ®Google Scholar
• Dillon NA, Peterson ND, Rosen BC, et al. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide. Antimicrob Agents Chemother 2014;58:7258-63
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2014;2:e34
   Google Scholar
• Shi W, Chen J, Feng J, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect 2014;3:e58
   PubMed Web of Science ®Google Scholar
• Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-7
   PubMed Web of Science ®Google Scholar
• Boshoff HI, Mizrahi V. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol 2000;182:5479-85
   PubMedGoogle Scholar
• Bamaga M, Wright DJ, Zhang H. Selection of in vitro mutants of pyrazinamide-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:275-81
   PubMed Web of Science ®Google Scholar
• Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio 2014;5:e01819-14
   PubMed Web of Science ®Google Scholar
• Bishop KS, Blumberg L, Trollip AP, et al. Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int J Tuberc Lung Dis 2001;5:952-7
   PubMedGoogle Scholar
• Huang TS, Lee SS, Tu HZ, et al. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob Agents Chemother 2003;47:3672-3
   PubMed Web of Science ®Google Scholar
• Miyagi C, Yamane N, Yogesh B, et al. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn Microbiol Infect Dis 2004;48:111-16
   PubMedGoogle Scholar
• Rodrigues Vde F, Telles MA, Ribeiro MO, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob Agents Chemother 2005;49:444-6
   PubMed Web of Science ®Google Scholar
• Chan RC, Hui M, Chan EW, et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007;59:866-73
   PubMed Web of Science ®Google Scholar
• Pandey S, Newton S, Upton A, et al. Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 2009;41:582-4
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, et al. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 2010;10:223
   PubMed Web of Science ®Google Scholar
• Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006;10:802-7
   PubMed Web of Science ®Google Scholar
• Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008;46:3459-64
   PubMed Web of Science ®Google Scholar
• Hou L, Osei-Hyiaman D, Zhang Z, et al. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 2000;124:227-32
   PubMed Web of Science ®Google Scholar
• Hirano K, Takahashi M, Kazumi Y, et al. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis 1997;78:117-22
   PubMedGoogle Scholar
• Lee KW, Lee JM, Jung KS. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci 2001;16:537-43
   PubMedGoogle Scholar
• Barco P, Cardoso RF, Hirata RD, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. J Antimicrob Chemother 2006;58:930-5
   PubMed Web of Science ®Google Scholar
• Bhuju S, Fonseca Lde S, Marsico AG, et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. Infect Genet Evol 2013;19:1-6
   PubMed Web of Science ®Google Scholar
• Doustdar F, Khosravi AD, Farnia P. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb Drug Resist 2009;15:251-6
   PubMed Web of Science ®Google Scholar
• Piersimoni C, Mustazzolu A, Giannoni F, et al. Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. J Clin Microbiol 2013;51:291-4
   PubMed Web of Science ®Google Scholar
• Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002;51:42-9
   PubMed Web of Science ®Google Scholar
• Chedore P, Bertucci L, Wolfe J, et al. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2010;48:300-1
   PubMed Web of Science ®Google Scholar
• Dormandy J, Somoskovi A, Kreiswirth BN, et al. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007;131:497-501
   PubMedGoogle Scholar
• Syre H, Ovreas K, Grewal HM. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay. J Antimicrob Chemother 2010;65:704-12
   PubMedGoogle Scholar
• Cui Z, Wang J, Lu J, et al. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J Clin Microbiol 2013;51:1374-80
   PubMedGoogle Scholar
• Heifets L, Sanchez T. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2000;38:1498-501
   PubMed Web of Science ®Google Scholar
• Zhang Y. Rapid molecular detection of pyrazinamide resistance: the way forward. Int J Tuberc Lung Dis 2015;19:128
   PubMedGoogle Scholar
• Boshoff HI, Mizrahi V. Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. J Bacteriol 1998;180:5809-14
   PubMedGoogle Scholar
• Guo M, Sun Z, Zhang Y. Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and pzaA. J Bacteriol 2000;182:3881-4
   PubMedGoogle Scholar
• Scorpio A, Collins D, Whipple D, et al. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol 1997;35:106-10
   PubMed Web of Science ®Google Scholar
• Petrella S, Gelus-Ziental N, Maudry A, et al. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide. PLoS One 2011;6:e15785
   PubMed Web of Science ®Google Scholar
• Vilcheze C, Weinrick B, Wong KW, et al. NAD+ auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol 2010;76:365-77
   PubMedGoogle Scholar
• Hammer-Jespersen K, Buxton RS, Hansen TD. A second purine nucleoside phosphorylase in Escherichia coli K-12. II. Properties of xanthosine phosphorylase and its induction by xanthosine. Mol Gen Genet 1980;179:341-8
   PubMedGoogle Scholar
• Dong WR, Sun CC, Zhu G, et al. New function for Escherichia coli xanthosine phosphorylase (xapA): genetic and biochemical evidences on its participation in NAD(+) salvage from nicotinamide. BMC Microbiol 2014;14:29
   PubMedGoogle Scholar
• Zhang Y, Wade MM, Scorpio A, et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52:790-5
   PubMed Web of Science ®Google Scholar
• Raynaud C, Laneelle MA, Senaratne RH, et al. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999;145(Pt 6):1359-67
   PubMedGoogle Scholar
• Zhang Y, Scorpio A, Nikaido H, et al. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999;181:2044-9
   PubMed Web of Science ®Google Scholar
• Sayahi H, Pugliese KM, Zimhony O, et al. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I. Chem Biodivers 2012;9:2582-96
   PubMedGoogle Scholar
• Sayahi H, Zimhony O, Jacobs WRJr, et al. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I. Bioorg Med Chem Lett 2011;21:4804-7
   PubMed Web of Science ®Google Scholar
• Zimhony O, Cox JS, Welch JT, et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000;6:1043-7
   PubMed Web of Science ®Google Scholar
• Thayil SM, Morrison N, Schechter N, et al. The role of the novel exopolyphosphatase MT0516 in Mycobacterium tuberculosis drug tolerance and persistence. PLoS One 2011;6:e28076
   Google Scholar
• Chuang YM, Belchis DA, Karakousis PC. The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence. MBio 2013;4:e00039-13
   PubMed Web of Science ®Google Scholar
• Singh R, Singh M, Arora G, et al. Polyphosphate deficiency in Mycobacterium tuberculosis is associated with enhanced drug susceptibility and impaired growth in guinea pigs. J Bacteriol 2013;195:2839-51
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y. PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob Agents Chemother 2007;51:2092-9
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang Y. PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65:1237-42
   PubMed Web of Science ®Google Scholar
• Wang C, Mao Y, Yu J, et al. PhoY2 of mycobacteria is required for metabolic homeostasis and stress response. J Bacteriol 2013;195:243-52
   PubMed Web of Science ®Google Scholar
• Shiba T, Tsutsumi K, Yano H, et al. Inorganic polyphosphate and the induction of rpoS expression. Proc Natl Acad Sci USA 1997;94:11210-15
   PubMedGoogle Scholar
• Hengge-Aronis R. Signal transduction and regulatory mechanisms involved in control of the sigma(S) (RpoS) subunit of RNA polymerase. Microbiol Mol Biol Rev 2002;66:373-95
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011;333:1630-2
   PubMed Web of Science ®Google Scholar
• Li J, Ji L, Shi W, et al. Trans-translation mediates tolerance to multiple antibiotics and stresses in Escherichia coli. J Antimicrob Chemother 2013;68:2477-81
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Y, Bi J, et al. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide. Mol Microbiol 2014. [Epub ahead of print]
   Google Scholar
• Mirabal NC, Yzquierdo SL, Lemus D, et al. Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010;48:2729-33
   PubMed Web of Science ®Google Scholar
• Martin A, Cubillos-Ruiz A, Von Groll A, et al. Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2008;61:123-7
   PubMed Web of Science ®Google Scholar
• Jeanguenin L, Lara-Nunez A, Rodionov DA, et al. Comparative genomics and functional analysis of the NiaP family uncover nicotinate transporters from bacteria, plants, and mammals. Funct Integr Genomics 2012;12:25-34
   PubMedGoogle Scholar
• Rodionov DA, Li X, Rodionova IA, et al. Transcriptional regulation of NAD metabolism in bacteria: genomic reconstruction of NiaR (YrxA) regulon. Nucleic Acids Res 2008;36:2032-46
   PubMedGoogle Scholar
• Raiol T, Ribeiro GM, Maranhao AQ, et al. Complete genome sequence of Mycobacterium massiliense. J Bacteriol 2012;194:5455
   PubMed Web of Science ®Google Scholar
• Ohashi K, Kawai S, Murata K. Secretion of quinolinic acid, an intermediate in the kynurenine pathway, for utilization in NAD+ biosynthesis in the yeast Saccharomyces cerevisiae. Eukaryot Cell 2013;12:648-53
   PubMedGoogle Scholar
• Llorente B, Dujon B. Transcriptional regulation of the Saccharomyces cerevisiae DAL5 gene family and identification of the high affinity nicotinic acid permease TNA1 (YGR260w). FEBS Lett 2000;475:237-41
   PubMedGoogle Scholar
• Herbert M, Sauer E, Smethurst G, et al. Nicotinamide ribosyl uptake mutants in Haemophilus influenzae. Infect Immun 2003;71:5398-401
   PubMedGoogle Scholar
• Sauer E, Merdanovic M, Mortimer AP, et al. PnuC and the utilization of the nicotinamide riboside analog 3-aminopyridine in Haemophilus influenzae. Antimicrob Agents Chemother 2004;48:4532-41
   PubMed Web of Science ®Google Scholar
• Jaehme M, Guskov A, Slotboom DJ. Crystal structure of the vitamin B3 transporter PnuC, a full-length SWEET homolog. Nat Struct Mol Biol 2014;21:1013-15
   PubMedGoogle Scholar
• Boshoff HI, Xu X, Tahlan K, et al. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem 2008;283:19329-41
   PubMed Web of Science ®Google Scholar
• Rodionova IA, Schuster BM, Guinn KM, et al. Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria. MBio 2014;5:1-9
   Google Scholar
• Lew JM, Kapopoulou A, Jones LM, et al. TubercuList - 10 years after. Tuberculosis (Edinb) 2011;91:1-7
   PubMed Web of Science ®Google Scholar
• Zimic M, Fuentes P, Gilman RH, et al. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinb) 2012;92:84-91
   PubMedGoogle Scholar
• French JB, Cen Y, Vrablik TL, et al. Characterization of nicotinamidases: steady state kinetic parameters, classwide inhibition by nicotinaldehydes, and catalytic mechanism. Biochemistry 2010;49:10421-39
   PubMedGoogle Scholar
• Gerdes SY, Scholle MD, D’Souza M, et al. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J Bacteriol 2002;184:4555-72
   PubMed Web of Science ®Google Scholar
• Osterman AL, Begley TP. A subsystems-based approach to the identification of drug targets in bacterial pathogens. Prog Drug Res 2007;64:131, 133-170
   PubMedGoogle Scholar
• Kim H, Shibayama K, Rimbara E, et al. Biochemical characterization of quinolinic acid phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv and inhibition of its activity by pyrazinamide. PLoS One 2014;9:e100062
   Google Scholar
• Cheng W, Roth J. Isolation of NAD cycle mutants defective in nicotinamide mononucleotide deamidase in Salmonella typhimurium. J Bacteriol 1995;177:6711-17
   PubMedGoogle Scholar
• Garavaglia S, Raffaelli N, Finaurini L, et al. A novel fold revealed by Mycobacterium tuberculosis NAD kinase, a key allosteric enzyme in NADP biosynthesis. J Biol Chem 2004;279:40980-6
   PubMed Web of Science ®Google Scholar
• Bellinzoni M, De Rossi E, Branzoni M, et al. Heterologous expression, purification, and enzymatic activity of Mycobacterium tuberculosis NAD(+) synthetase. Protein Expr Purif 2002;25:547-57
   PubMedGoogle Scholar
• Sharma V, Grubmeyer C, Sacchettini JC. Crystal structure of quinolinic acid phosphoribosyltransferase from Mycobacterium tuberculosis: a potential TB drug target. Structure 1998;6:1587-99
   PubMedGoogle Scholar
• Houtkooper RH, Canto C, Wanders RJ, et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194-223
   PubMed Web of Science ®Google Scholar
• Sorci L, Ruggieri S, Raffaelli N. NAD homeostasis in the bacterial response to DNA/RNA damage. DNA Repair (Amst) 2014;23:17-26
   PubMedGoogle Scholar
• Srivastava SK, Dube D, Tewari N, et al. Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I. Nucleic Acids Res 2005;33:7090-101
   PubMed Web of Science ®Google Scholar
• Noy T, Xu H, Blanchard JS. Acetylation of acetyl-CoA synthetase from Mycobacterium tuberculosis leads to specific inactivation of the adenylation reaction. Arch Biochem Biophys 2014;550-551:42-9
   PubMedGoogle Scholar
• North BJ, Verdin E. Sirtuins: sir2-related NAD-dependent protein deacetylases. Genome Biol 2004;5:224
   PubMed Web of Science ®Google Scholar
• Hayden JD, Brown LR, Gunawardena HP, et al. Reversible acetylation regulates acetate and propionate metabolism in Mycobacterium smegmatis. Microbiology 2013;159:1986-99
   PubMed Web of Science ®Google Scholar
• Gu J, Deng JY, Li R, et al. Cloning and characterization of NAD-dependent protein deacetylase (Rv1151c) from Mycobacterium tuberculosis. Biochemistry (Mosc) 2009;74:743-8
   PubMedGoogle Scholar
• Jordahl C, Des Prez R, Deuschle K, et al. Ineffectiveness of nicotinamide and isoniazid in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1961;83:899-900
   PubMedGoogle Scholar
• Morisaki N, Hashimoto Y, Furihata K, et al. Structures of ADP-ribosylated rifampicin and its metabolite: intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756. J Antibiot (Tokyo) 2000;53:269-75
   PubMedGoogle Scholar
• Quan S, Imai T, Mikami Y, et al. ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene. Antimicrob Agents Chemother 1999;43:181-4
   PubMedGoogle Scholar
• Baysarowich J, Koteva K, Hughes DW, et al. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc Natl Acad Sci USA 2008;105:4886-91
   PubMed Web of Science ®Google Scholar
• Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997;41:2456-60
   PubMed Web of Science ®Google Scholar
• Fonseca Lde S, Marsico AG, Vieira GB, et al. Correlation between resistance to pyrazinamide and resistance to other antituberculosis drugs in Mycobacterium tuberculosis strains isolated at a referral hospital. J Bras Pneumol 2012;38:630-3
   PubMedGoogle Scholar
• Wang XD, Gu J, Wang T, et al. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation. Mol Microbiol 2011;82:1375-91
   PubMedGoogle Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes -. Release 72.1, December 1, 2014 Nucleic Acids Res 2000;28:27-30
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S, Sato Y, et al. Data, information, knowledge and principle: back to metabolism in KEGG. - Release 72.1, December 1, 2014 Nucleic Acids Res 2014;42:D199-205
   PubMed Web of Science ®Google Scholar
• Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009;15:20-8
   PubMed Web of Science ®Google Scholar
• Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001;183:1168-74
   PubMed Web of Science ®Google Scholar
• Konno K, Feldmann FM, McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967;95:461-9
   PubMed Web of Science ®Google Scholar
• Cynamon MH, Klemens SP, Chou TS, et al. Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem 1992;35:1212-15
   PubMedGoogle Scholar
• Speirs RJ, Welch JT, Cynamon MH. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob Agents Chemother 1995;39:1269-71
   PubMedGoogle Scholar
• Cynamon MH, Gimi R, Gyenes F, et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J Med Chem 1995;38:3902-7
   PubMed Web of Science ®Google Scholar
• Bergmann KE, Cynamon MH, Welch JT. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters. J Med Chem 1996;39:3394-400
   PubMedGoogle Scholar
• Yamamoto S, Toida I, Watanabe N, et al. In vitro antimycobacterial activities of pyrazinamide analogs. Antimicrob Agents Chemother 1995;39:2088-91
   PubMedGoogle Scholar
• Simões MF, Valente E, Gómez MJ, et al. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis. Eur J Pharm Sci 2009;37:257-63
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. WHO/HTM/TB/2009.422 World Health Organization; Geneva, Switzerland: 2009
   Google Scholar
• Hoffner S, Ängeby K, Sturegård E, et al. Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis 2013;17:1486-90
   PubMed Web of Science ®Google Scholar
• World Health Organization. Emergency update. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO; Geneva, Switzerland: 2008
   Google Scholar
• Ängeby K, Juréen P, Kahlmeter G, et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 2012;90:693-8
   PubMed Web of Science ®Google Scholar
• Gumbo T, Chigutsa E, Pasipanodya J, et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother 2014;69:2420-5
   PubMedGoogle Scholar
• BD Diagnostic Systems. BACTEC™ MGIT™ 960 PZA kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. Product and Procedure Manual
   Google Scholar
• BD Diagnostic Systems. BACTEC™ 460TB. Product and Procedure Manual
   Google Scholar
• National Committee for Clinical Laboratory Standards. Approved standard M24-A. Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes. NCCLS; Wayne, Pa: 2001
   Google Scholar
• Miller MA, Thibert L, Desjardins F, et al. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol 1995;33:2468-70
   PubMed Web of Science ®Google Scholar
• Hewlett DJr, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995;273:916-17
   PubMed Web of Science ®Google Scholar
• Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011;55:4499-505
   PubMed Web of Science ®Google Scholar
• Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol 2014;52:291-7
   PubMed Web of Science ®Google Scholar
• Karuppiah V, Thistlethwaite A, Dajani R, et al. Structure and Mechanism of the Bifunctional CinA Enzyme from Thermus thermophilus. J Biol Chem 2014;289:33187-97
   PubMedGoogle Scholar
• Pugmire MJ, Ealick SE. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 2002;361:1-25
   PubMed Web of Science ®Google Scholar